A comprehensive systematic review and multi-level meta-analysis has quantified the significant impact of virtual reality (VR) interventions on reducing anxiety symptoms among women undergoing gynecological examinations and surgeries. The findings, published recently, indicate that VR offers a promising non-pharmacological approach to managing psychological distress in these sensitive medical contexts, though significant heterogeneity among studies necessitates careful interpretation and further research. Virtual Reality as a Tool for Anxiety Reduction in Gynecological Care Anxiety is a pervasive issue, particularly for women, and its prevalence has seen a notable increase globally. This heightened vulnerability is often linked to societal expectations and increased responsibilities. In the realm of women’s health, gynecological examinations and surgeries, while essential for diagnosis and treatment, frequently trigger significant anxiety. These procedures can involve intimate examinations, concerns about pain, and apprehension regarding potential health outcomes, leading to tension, unease, and even avoidance of necessary medical care. The impact of anxiety extends beyond immediate discomfort. In gynecological examinations, it can lead to delayed or missed screenings, impacting long-term health maintenance. For surgical procedures, anxiety can persist through pre-operative, peri-operative, and post-operative phases, diminishing patient experience, potentially interfering with medical procedures, and prolonging recovery. Given these challenges, the search for effective, safe, and non-pharmacological interventions to manage anxiety in this population is paramount. Virtual reality technology has emerged as a potential solution. By creating immersive, controllable virtual environments, VR allows individuals to engage in multisensory experiences that can divert attention from distressing stimuli, modulate emotional responses, and promote relaxation. Previous research has demonstrated VR’s efficacy in reducing anxiety in various medical settings, and this latest meta-analysis specifically targets its application within the gynecological domain. Rigorous Methodology for Evidence Synthesis The study adhered to the stringent guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to ensure the quality and transparency of its findings. Researchers conducted a systematic search of major academic databases, including PubMed, Web of Science, PsycINFO, and the Cochrane Library, up to January 5, 2026. The search focused on randomized controlled trials (RCTs) that evaluated the effects of VR interventions on anxiety symptoms in women undergoing gynecological examinations or surgeries. The inclusion criteria were specific: studies must be RCTs comparing VR interventions against control groups (no intervention, routine care, or standard medical/pharmacological interventions); the participants must be women undergoing gynecological examinations or surgeries; anxiety symptoms must be measured using validated, standardized scales; and the research must be published in English. Exclusion criteria encompassed non-experimental studies, secondary research, and studies with poorly structured or non-standardized interventions. A multi-level random-effects model was employed to pool effect sizes, specifically the Standardized Mean Difference (SMD), to account for potential correlations among effect sizes within studies. The analysis also incorporated rigorous assessments of heterogeneity, tests for publication bias, subgroup analyses, meta-regressions, and Bayesian dose-response analyses to explore sources of variation and identify optimal intervention parameters. The quality of the included studies was assessed using the Risk of Bias tool (RoB 2), and the overall quality of evidence was evaluated using the GRADE criteria. Key Findings: VR’s Efficacy and Its Nuances The meta-analysis synthesized data from 12 RCTs, encompassing a total of 1,237 participants published between 2019 and 2025. The results revealed a significant reduction in anxiety symptoms among women receiving VR interventions during the intervention period. The pooled effect size was calculated at an SMD of -0.47 (95% Confidence Interval: -0.73 to -0.21, p < 0.001), indicating a small-to-moderate effect. This finding suggests that VR is generally effective in alleviating anxiety in this population. However, the study also highlighted substantial heterogeneity among the included trials (I² = 77%, p < 0.001). This variability underscores the importance of considering specific factors that may influence VR’s effectiveness. The quality of evidence, assessed using the GRADE criteria, was rated as moderate, reflecting both the strengths of the included RCTs and the presence of significant inconsistency. To delve deeper into the sources of this heterogeneity, several subgroup analyses were conducted. These analyses indicated that VR interventions tended to show more consistent and significant effects in several specific scenarios: Non-Invasive Procedures: VR demonstrated a stronger impact when used for non-invasive gynecological procedures compared to moderately invasive or highly invasive ones. For non-invasive procedures, the SMD was -0.78 (95% CI: -1.19 to -0.38). VR Alone: When VR was used as a standalone intervention, its anxiety-reducing effect was more pronounced (SMD = -0.64, 95% CI: -0.92 to -0.35) compared to when it was combined with other interventions. Anxiety Assessment Tool: The use of the Numerical Rating Scale (NRS) for anxiety assessment yielded more consistent results (SMD = -0.61) compared to other scales, suggesting potential differences in how various tools capture VR’s impact. Intervention Duration: Interventions lasting between 5 to 10 minutes showed a statistically significant anxiety-relieving effect (SMD = -0.53, 95% CI: -0.76 to -0.30). Furthermore, linear meta-regression analyses identified key moderators influencing the efficacy of VR interventions. These included the country/region where the study was conducted, the specific anxiety assessment tool used, and the methodological quality of the study (as determined by the RoB 2 assessment). Exploring Dose-Response and Optimal Parameters Beyond identifying general trends, the research employed non-linear analyses, including Bayesian dose-response modeling, to explore potential relationships between intervention parameters and therapeutic outcomes. These exploratory analyses suggested that while variables like age and sample size might have non-linear associations with VR’s effectiveness, the current data distribution limited the certainty of these findings. A notable focus was placed on intervention duration. The dose-response analysis pointed towards a potential optimal duration range of approximately 9 to 13 minutes for VR interventions. While this finding is considered exploratory due to limited data, it offers a preliminary guideline for future research and clinical implementation. The pooled effect estimate was also translated into a more clinically interpretable measure on the Visual Analog Scale (VAS) 0-10, suggesting an average reduction of approximately 1.32 points, which is comparable to or exceeds the minimal clinically important difference (MCID) of 1 point. However, the confidence interval for this translation did not fully extend beyond the MCID, warranting a cautious interpretation of its clinical significance. Implications for Clinical Practice and Future Research The findings of this meta-analysis strongly suggest that VR is a valuable non-pharmacological adjunct for managing anxiety in women undergoing gynecological procedures. Its immersive nature and ability to divert attention make it a practical tool for enhancing patient comfort and potentially improving healthcare experiences. The observed benefits were particularly pronounced in less invasive settings and when VR was utilized as a standalone intervention. However, the substantial heterogeneity across studies underscores that VR is not a one-size-fits-all solution. The effectiveness can be influenced by the type of procedure, the specific VR content, the duration of the intervention, and even cultural factors related to the geographical location of the study. The finding that VR was less effective in highly invasive procedures suggests that for more complex surgeries, VR might need to be integrated with other therapeutic strategies. The study’s limitations, including the considerable heterogeneity, the reliance on aggregate data, and potential risks of bias in some included studies, highlight the need for further rigorous research. Future multicenter studies with larger sample sizes and standardized methodologies are crucial. These studies should aim to: Clarify Procedure-Specific Efficacy: Investigate the effectiveness of VR across a wider range of gynecological procedures, differentiating between invasiveness levels and specific conditions. Optimize Intervention Parameters: Further refine the optimal duration, content, and delivery methods of VR interventions based on robust data. Assess Long-Term Effects: Evaluate the sustained impact of VR on anxiety and its potential influence on patient outcomes beyond the immediate intervention period. Standardize Measurement Tools: Encourage the use of consistent and validated anxiety assessment tools to facilitate more direct comparisons across studies. In conclusion, this meta-analysis provides robust evidence for the efficacy of virtual reality interventions in reducing anxiety symptoms among women undergoing gynecological examinations and surgeries. As a safe, accessible, and non-pharmacological tool, VR holds significant promise for improving patient care in this critical area of women’s health. Continued research and careful implementation guided by these findings will be essential to fully harness its therapeutic potential. Post navigation Negotiating Ethnolinguistic Identity in a Multilingual Society: Social Meaning and Linguistic Choice in Namibian German
